Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections

Expert Opinion on Investigational Drugs

Volumn 12, Issue 7, 2003, Pages 1165-1177

  Blasi, Francesco ^a   Tarsia, Paolo ^b   Cosentini, Roberto ^b   Cazzola, Mario ^c   Allegra, Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Antimicrobial resistance; Community acquired respiratory infections; Fluoroquinolones; Pharmacokinetic

Indexed keywords

ALUMINUM; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DIGOXIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; IRON; LEVOFLOXACIN; MACROLIDE; MAGNESIUM; METICILLIN; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZINC;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TARGETING; DRUG USE; EMPIRICISM; FOOD DRUG INTERACTION; HEADACHE; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LONG QT SYNDROME; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MORTALITY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PHARMACODYNAMICS; PHOTOSENSITIVITY; PNEUMONIA; POSTANTIBIOTIC EFFECT; PRACTICE GUIDELINE; PRURITUS; PUBLIC HEALTH; RASH; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; VERTIGO;

EID: 0038783384     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.7.1165     Document Type: Review

References (83)

1. MITSUYAMA J: Structures of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae. J. Antimicrob. Chemother. (1999) 44:201-207.
2. ALOVERO F, PAN X-S, MORRIS JE, MANZO RH, FISHER LM: Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisometase IV to gyrase. Antimicrob. Agents Chemother. (2000) 44:320-325.
3. SCHMITZ FJ, HOFMANN B, HANSEN B et al.: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. (1998) 41:481-484.
4. CHANT SK, SINGH M, CHATTERJEE NR: The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr. Pharm. Design (2001) 7:313-337.
5. SCHENTAG JJ: Pharmacokynetic and pharmacodynamic predictors of antimicrobial efficacy: Moxifloxacin and Streptococcus pneumoniae. J. Chemother. (2002) 14(S2):13-21.
6. 0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J. Antimicrob. Chemother. (2003) 51:905-911.
7. CROISIER D, CHAVANET P, LEQUEU C et al.: Efficacy and pharmacodynamic of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J. Antimicrob. Chemother. (2002) 50:349-360.
8. BLONDEAU JM: Expanded activity and utility of the new fluorquinolones: a review. Clin. Ther. (1991) 21:3-40.
9. LACRETA FP, KOLLIA GD, DUNCAN G et al.: Age and Gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy (2000) 20:67S-75S.
10. CHIEN SC, CHOW AT, NATARAJAN J et al.: Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral does of levofloxacin in healthy subjects. Antimicrob. Agents Chemother. (1997) 41:1562-1565.
11. NIGHTINGALE CH: Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy (2000) 20:245-256.
12. FORREST A, NIX DE, BALLOW CH, GOSS TF, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. (1993) 37:1073-1081.
13. DALHOFF A: Pharmacodynamics of fluoroquinolones. J. Antimicrob. Chemother. (1999) 43(Suppl. B):51-59.
14. DONG Y, ZHAO X, KREISWIRTH B et al.: Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2000) 44:1756-1758.
15. BLONDEAU J, ZHAO X, HANSEN G et al.: Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemotber. (2001) 45:433-438.
16. ZHAO X, EISNER W, PERL-ROSENTHAL N, KREISWIRTH B, DRLICA K: Mutant prevention concentration of garenoxacin for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47:1023-1027.
17. JONES RN, MUTNICK A, BIEDENBACH D: Garenoxacin (BMS284756) activity against 8,686 S. pneumoniae including tentative susceptibility testing criteria. 42nd ICAAC, San Diego, CA, USA (2002):151 (Abstract E58).
18. HOBAN DJ, PALATNICK L, SMITH H, NICHOL K, HOBAN C, ZHANEL GG: Activity of BMS284756 and marketed fluoroquinolones against lower respiratory tract pathogens: results of a 3 year Canadian Surveillance study. 42nd ICAAC, San Diego, CA, USA (2002):153 (Abstract E64).
19. BOZDOGAN B, KELLY L, JACOBS MR, APPELBAUM PC: Activity of DK507k, a new fluoroquinolone, against quinolone non-susceptible Streptococcus pneumoniae compared to ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin and sitafloxacin. 42nd ICAAC, San Diego, CA, USA (2002):189 (Abstract F571).
20. CLARK CL, JACOBS MR, APPELBAUM PC: Time-kill study of antipneumococcal activity of DK507k, a new fluoroquinolone, compared to 5 other agents. 42nd ICAAC, San Diego CA, USA (2002):190 (Abstract F574).
21. LIN G, PATEL M, GUPTE S et al.: Time-kill analysis of the antipneumococcal activity of two new quinolones, WCK771A and WCK919, compared to five other quinolones. 42nd ICAAC, San Diego CA, USA (2002):186 (Abstract F559).
22. DALHOFF A, SCHMITZ FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22:203-221.
23. HOBAN DJ, BOUCHILLON SK, JOHNSON JL et al.: Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent european clinical isolates from a global surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20:814-819.
24. DUBOIS J, ST-PIERRE C: In vitro activity of ABT 492 versus quinolones and macrolides against Legionella spp. 42nd ICAAC, San Diego, CA, USA (2002):185 (Abstract F553).
25. MILATOVICH D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In vitro activities of sitafloxacin and six other quinolones against 8.796 clinical bacterial isolates. Antimicrob. Agents Chemother. (2000) 44:1102-1107.
26. ALDRIDGE KE: Increased activity of a new chlorofluoroquinolone, BAY y3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob. Agents Chemother. (1994) 38:1671-1674.
27. APPELBAUM PC, PATEL M, GUPTE S et al.: Anti-anaerobic activity of two new quinolones, WCK771A and WCK919, compared to nine other agents. 42nd ICAAC, San Diego, CA, USA (2002):187 (Abstract F561).
28. DAVIES BI, MAESEN FP: Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J. Antimicrob. Chemother. (1999) 43(Suppl. C):83-90.
29. DE ABATE CA, RUSSEL M, MCELVAINE P et al.: Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir. Care (1997) 42:206-213.
30. HABIB MP, RUSSELL M, DE ABATE CA et al.: Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of chronic bronchitis. Infect. Dis. Clin. Practice (1998) 7:1-9.
31. SHAH PM, MAESEN FP, DOLMANN A et al.: Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study. J. Antimicrob. Chemother. (1999) 43:529-539.
32. WEISS LR: Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin. Ther. (2002) 24:1414-1425.
33. MASTERTON RG, BURLEY CJ: Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents (2001) 18:503-512.
34. RAMIREZ A, MOLINA J, HOFMANN A et al.: Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: clinical trial results. J. Respir. Dis. (1999) 20(11):30s-39s.
35. DE ABATE CA, MCIVOR RA, MCELVAINE P et al.: Gatifloxacin versus cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J. Respir. Dis. (1999) 20(11):23s-29s.
36. WILSON R, KUBIN R, BALLIN I et al.: Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. (1999) 44:501-513.
37. CHODOSH S, DEABATE CA, HAVERSTOCK D et al.: Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med. (2000) 94:18-27.
38. KREIS S, HERRERA N, GOLZAR N et al.: A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J. Clin. Outcomes Manage. (2000) 7:3337.
39. DEABATE CA, MATTHEW CP, WARNER JH et al.: The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir. Med. (2000) 94:1029-1037.
40. SCHABERG T, BALLIN I, HUCHON G et al.: A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbations of chronic bronchitis. J. Int. Med. Res. (2001) 29:314-328.
41. LORENZ J, THATE-WASCHKE IM, MAST O et al.: Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J. Int. Med. Res. (2001) 29:74-86.
42. FILE TM, SEGRETI J, DUBAR L et al.: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. (1997) 41:1965-1972.
43. GEDDES AM, THALER M, SCHONWALD S et al.: Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomised trial. J. Antimicrob. Chemother. (1999) 44:799-810.
44. SULLIVAN J, MCELROY AD, HONSINGER RW et al.: Treating community-acquired pneumonia with once daily gatifloxacin versus once daily levofloxacin. J. Respir. Dis. (1999) 20(S11):49s-59s.
45. RAMIREZ JA, NGUYEN TH, TELLIER G et al.: Treating community-acquired pneumonia with once daily gatifloxacin versus twice daily clarithromycin. J. Respir. Dis. (1999) 20(S11):40s-48s.
46. FOGARTY C, DOWELL ME, ELLISON WT et al.: Treating community-acquired pneumonia in hospitalised patients: gatifloxacin versus ceftriaxone/clarithromycin. J. Respir. Dis. (1999) 20(S11):S60-S69.
47. DRESSER LD, NIEDERMAN MS, PALADINO JA: Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest (2001) 119:1439-1448.
48. FOGARTY C, GROSSMAN C, WILLIAMS J et al.: Efficacy and safety of moxifloxacin versus clarithromycin for community-acquired pneumonia. Infect. Med. (1999) 16:748-763.
49. HOEFFKEN G, MEYER HP, WINTER J et al.: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir. Med. (2001) 95:553-564.
50. PETITPRETZ P, ARVIS P, MARCEL M et al.: Oral moxifloxacin versus high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest (2001) 119:185-195.
51. FINCH R, SCHURMANN D, COLLINS O et al.: Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared to sequential i.v and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Drugs (2002) 62:13-59.
52. ANDREWS JM, HONEYBOURNE, D, JEVONS G, BRENWALD NP, CUNNINGHAM B, WISE R: Concentration of levofloxacin in the respiratory tract following a single oral doses in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. (1997) 40:573-577.
53. BALL P, FERNALD A, TILLOTSON G: Therapeutical advances of new fluoroquinolones. Expert Opin. Invest. Drugs (1998) 7:761-783.
54. LEGG JM, BINT AJ: Will pneumococci put quinolones in their place. J. Antimicrob. Chemother. (1999) 44:425-427.
55. CHEN DK, MCGEER A, DE AZAVEDO JC, LOW DE: Decreased susceptibility of Sheptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. (1999) 341:233-239.
56. ZHANEL GG, EMIS K, VERCAINGE L et al.: A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs (2002) 62:13-59.
57. SCHELD WM: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. (2003) 9:1-9.
58. HO PL, YUNG RW, TSANG DN et al.: Increasing resistance of S. pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. (2001) 48:659-665.
59. DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PL, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721-1729.
60. NIEDERMAN MS: Guidelines for the management of community-acquired pneumonia. Med. Clin. North Am. (2001) 85:1493-1509.
61. FUKUDA H, HIRAMATSU K: Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1999) 43:410-412.
62. PIDDOCK LJ: Mechanisms of resistance to fluoroquinolones: state ofthe art 1992-1994. Drugs (1995) 49(2):29-35.
63. HOOPER DC: Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. (2001) 7:337-341.
64. HOOPER DC: Mechanism of quinolone resistance. Drug Resistance Updates (1999) 2:38-55.
65. KÖHLER T, PECHÈRE JC: Bacterial resistance to quinolones. In: The Quinolones (2nd Ed.). VT Andriole (Ed.), Academic Press, San Diego, CA, USA (1998):117-142.
66. BOSWELL FJ, ANDREWS JM, JEVONS G, WISE R: Comparison of in vitro activities of several new quinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J. Antimicrob. Chemother. (2002) 50:495-502.
67. BOLHUIS H, VAV VEEN HW, POOLMAN B, DRIESSEN AJ et al.: Mechanisms of multidrug transporters. FEMS Microbiol. Rev. (1997) 21:55-84.
68. MARTÌNEZ-MARTÌNEZ L, PASCUAL A, JACOBY GA. Quinolone resistance from a transferable plasmid. Lancet (1998) 351:797-799.
69. DRILICA K: A strategy for fighting antibiotic resistance. ASM News (2001) 67:27-33.
70. BRENWALD NP, GILL MJ, WISE R: Prevalence of a putative efflux mechanism among fluoroquinolone-clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1998) 42:2032-2035.
71. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR (2001) 50(37):800-804.
72. DAVIDSON R, CAVALCANTI R, BRUNTON JL et al.: Brief report: resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. (2002) 346:747-750.
73. WEISS K, RESTIERI C, GAUTHIER R et al.: A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin. Infect. Dis. (2001) 33:517-522.
74. HO PL, TSE WS, TSANG KWT et al.: Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case control study. Clin. Infect. Dis. (2001) 33:701-707.
75. URBAN C, RAHMAN N, ZHAO X, MARIANO S et al.: Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. (2001) 184:794-798.
76. HOOPER DC: New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. (2000) 30:243-254.
77. MENZIES DJ, DORSAINVIL PA, CUNHA BA et al.: Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am. J. Med. (2002) 113:232-234.
78. STHALMANN R, LODE H: Toxicity of quinolones. Drugs (1999) 58(Suppl. 2):37-42.
79. LEWIS JR, GUMS JG, DICKENSHEETS DL: Levofloxacin-induced bilateral Achilles tendinitis. Ann. Pharmacother. (1999) 33:792-795.
80. BLONDEAU JM: Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin. Investig. Drugs (2001) 10:213-237.
81. BALL P, MANDELL L, NIKI Y, TILLOTSON G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety (1999) 21:407-421.
82. WILSON R, LANGAN C, BALL P, BATEMAN K, PYPSTRA R: Oral gemifloxacin once daily for five days compared with sequential therapy with IV ceftriaxone/oral cefuroxime (max of 10 days) in the treatment of hospitalised patients with acute exacerbations of chronic bronchitis. Respir. Med. (2003) 97:242-249.
83. LODE H, FILE TM, MANDELL LA, BALL P, PYPSTRA R, THOMAS M: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalised with community-acquired pneumonia: randomized, open label, multicenter study of clinical efficacy and tolerability. Clin. Ther. (2002) 24:1915-1936.